These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33832966)

  • 1. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.
    Boonen A; Putrik P; Marques ML; Alunno A; Abasolo L; Beaton D; Betteridge N; Bjørk M; Boers M; Boteva B; Fautrel B; Guillemin F; Mateus EF; Nikiphorou E; Péntek M; Pimentel Santos F; Severens JL; Verstappen SMM; Walker-Bone K; Wallman JK; Ter Wee MM; Westhovens R; Ramiro S
    Ann Rheum Dis; 2021 Sep; 80(9):1116-1123. PubMed ID: 33832966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider.
    Marques ML; Alunno A; Boonen A; Ter Wee MM; Falzon L; Ramiro S; Putrik P
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33542048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2021 EULAR points to consider to support people with rheumatic and musculoskeletal diseases to participate in healthy and sustainable paid work.
    Boonen A; Webers C; Butink M; Barten B; Betteridge N; Black DC; Bremander A; Boteva B; Brzezińska O; Chauhan L; Copsey S; Guimarães V; Gignac M; Glaysher J; Green F; Hoving JL; Marques ML; Smucrova H; Stamm TA; Wiek D; Wilkie R; Woolf AD; Burmester GR; Bijlsma JW; Verstappen SMM
    Ann Rheum Dis; 2023 Jan; 82(1):57-64. PubMed ID: 36109139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.
    Dejaco C; Putrik P; Unger J; Aletaha D; Bianchi G; Bijlsma JW; Boonen A; Cikes N; Finckh A; Gossec L; Kvien TK; Madruga Dias J; Matteson EL; Sivera F; Stamm TA; Szekanecz Z; Wiek D; Zink A; Ramiro S; Buttgereit F
    RMD Open; 2018; 4(2):e000780. PubMed ID: 30714579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology.
    Courvoisier DS; Lauper K; Kedra J; de Wit M; Fautrel B; Frisell T; Hyrich KL; Iannone F; Machado PM; Ørnbjerg LM; Rotar Z; Santos MJ; Stamm TA; Stones SR; Strangfeld A; Bergstra SA; Landewé RBM; Finckh A
    Ann Rheum Dis; 2022 Jun; 81(6):780-785. PubMed ID: 35058229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.
    Zabotti A; De Marco G; Gossec L; Baraliakos X; Aletaha D; Iagnocco A; Gisondi P; Balint PV; Bertheussen H; Boehncke WH; Damjanov NS; de Wit M; Errichetti E; Marzo-Ortega H; Protopopov M; Puig L; Queiro R; Ruscitti P; Savage L; Schett G; Siebert S; Stamm TA; Studenic P; Tinazzi I; Van den Bosch FE; van der Helm-van Mil A; Watad A; Smolen JS; McGonagle DG
    Ann Rheum Dis; 2023 Sep; 82(9):1162-1170. PubMed ID: 37295926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
    van der Togt CJT; Van den Bemt B; Aletaha D; Alten R; Chatzidionysiou K; Galloway J; Isaac J; Mulleman D; Verschueren P; Vulto AG; Welsing PMJ; Verhoef L; den Broeder AA
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36863753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
    Mankia K; Siddle HJ; Kerschbaumer A; Alpizar Rodriguez D; Catrina AI; Cañete JD; Cope AP; Daien CI; Deane KD; El Gabalawy H; Finckh A; Holers VM; Koloumas M; Ometto F; Raza K; Zabalan C; van der Helm-van Mil A; van Schaardenburg D; Aletaha D; Emery P
    Ann Rheum Dis; 2021 Oct; 80(10):1286-1298. PubMed ID: 34362746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
    Rodríguez-Carrio J; Burska A; Conaghan PG; Dik WA; Biesen R; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Rönnblom L; Versnel MA; Vital EM
    Ann Rheum Dis; 2023 Jun; 82(6):754-762. PubMed ID: 36858821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
    Krieckaert CL; van Tubergen A; Gehin JE; Hernández-Breijo B; Le Mélédo G; Balsa A; Böhm P; Cucnik S; Elkayam O; Goll GL; Hooijberg F; Jani M; Kiely PD; McCarthy N; Mulleman D; Navarro-Compán V; Payne K; Perry ME; Plasencia-Rodriguez C; Stones SR; Syversen SW; de Vries A; Ward KM; Wolbink G; Isaacs JD
    Ann Rheum Dis; 2023 Jan; 82(1):65-73. PubMed ID: 35551063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs).
    Dejaco C; Machado PM; Carubbi F; Bosch P; Terslev L; Tamborrini G; Sconfienza LM; Scirè CA; Ruetten S; van Rompay J; Proft F; Pitzalis C; Obradov M; Moe RH; Mascarenhas VV; Malattia C; Klauser AS; Kent A; Jans L; Hartung W; Hammer HB; Duftner C; Balint PV; Alunno A; Baraliakos X
    Ann Rheum Dis; 2022 Jun; 81(6):760-767. PubMed ID: 34893469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.
    Nikiphorou E; Santos EJF; Marques A; Böhm P; Bijlsma JW; Daien CI; Esbensen BA; Ferreira RJO; Fragoulis GE; Holmes P; McBain H; Metsios GS; Moe RH; Stamm TA; de Thurah A; Zabalan C; Carmona L; Bosworth A
    Ann Rheum Dis; 2021 Oct; 80(10):1278-1285. PubMed ID: 33962964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
    Agca R; Heslinga SC; Rollefstad S; Heslinga M; McInnes IB; Peters MJ; Kvien TK; Dougados M; Radner H; Atzeni F; Primdahl J; Södergren A; Wallberg Jonsson S; van Rompay J; Zabalan C; Pedersen TR; Jacobsson L; de Vlam K; Gonzalez-Gay MA; Semb AG; Kitas GD; Smulders YM; Szekanecz Z; Sattar N; Symmons DP; Nurmohamed MT
    Ann Rheum Dis; 2017 Jan; 76(1):17-28. PubMed ID: 27697765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases.
    de Thurah A; Bosch P; Marques A; Meissner Y; Mukhtyar CB; Knitza J; Najm A; Østerås N; Pelle T; Knudsen LR; Šmucrová H; Berenbaum F; Jani M; Geenen R; Krusche M; Pchelnikova P; de Souza S; Badreh S; Wiek D; Piantoni S; Gwinnutt JM; Duftner C; Canhão HM; Quartuccio L; Stoilov N; Prior Y; Bijlsma JW; Zabotti A; Stamm TA; Dejaco C
    Ann Rheum Dis; 2022 Aug; 81(8):1065-1071. PubMed ID: 35470160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
    Gossec L; Baraliakos X; Kerschbaumer A; de Wit M; McInnes I; Dougados M; Primdahl J; McGonagle DG; Aletaha D; Balanescu A; Balint PV; Bertheussen H; Boehncke WH; Burmester GR; Canete JD; Damjanov NS; Kragstrup TW; Kvien TK; Landewé RBM; Lories RJU; Marzo-Ortega H; Poddubnyy D; Rodrigues Manica SA; Schett G; Veale DJ; Van den Bosch FE; van der Heijde D; Smolen JS
    Ann Rheum Dis; 2020 Jun; 79(6):700-712. PubMed ID: 32434812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases.
    Najm A; Nikiphorou E; Kostine M; Richez C; Pauling JD; Finckh A; Ritschl V; Prior Y; Balážová P; Stones S; Szekanecz Z; Iagnocco A; Ramiro S; Sivera F; Dougados M; Carmona L; Burmester G; Wiek D; Gossec L; Berenbaum F
    RMD Open; 2019; 5(2):e001014. PubMed ID: 31565245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.
    Bech B; Primdahl J; van Tubergen A; Voshaar M; Zangi HA; Barbosa L; Boström C; Boteva B; Carubbi F; Fayet F; Ferreira RJO; Hoeper K; Kocher A; Kukkurainen ML; Lion V; Minnock P; Moretti A; Ndosi M; Pavic Nikolic M; Schirmer M; Smucrova H; de la Torre-Aboki J; Waite-Jones J; van Eijk-Hustings Y
    Ann Rheum Dis; 2020 Jan; 79(1):61-68. PubMed ID: 31300458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EULAR recommendations for patient education for people with inflammatory arthritis.
    Zangi HA; Ndosi M; Adams J; Andersen L; Bode C; Boström C; van Eijk-Hustings Y; Gossec L; Korandová J; Mendes G; Niedermann K; Primdahl J; Stoffer M; Voshaar M; van Tubergen A;
    Ann Rheum Dis; 2015 Jun; 74(6):954-62. PubMed ID: 25735643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.